BioCentury | Jul 31, 2020
Distillery Therapeutics

ADORA2B agonism for obesity and aging-induced sarcopenia

DISEASE CATEGORY: Endocrine/metabolic; musculoskeletal INDICATION: Obesity; musculoskeletal Promoting adenosine signaling through ADORA2B could treat obesity and aging-induced sarcopenia. In brown adipose tissue biopsies from lean and overweight individuals, ADORA2B expression was lower in older individuals...
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

Among four new biotech listings Friday, three priced upsized IPOs that each delivered more than $200 million in proceeds, but none of the quartet enjoyed the kind of satisfying first-day pop other biotechs have had...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

June has already seen 13 biopharmas raise more than a total of $4.7 billion from NASDAQ IPOs, and biotechs are continuing to line up for public market debuts (see “Biotech IPOs on NASDAQ Maintain Momentum”...
BioCentury | Jun 24, 2020
Deals

Gilead gains access to tumor myeloid targets via Pionyr partnership

Gilead’s tie-up with Pionyr marks the big biotech’s fifth cancer deal this year and gives it access to mAbs against immunosuppressive tumor myeloid cells. In an agreement announced Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) will pay...
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

iTeos Therapeutics S.A. made several hires Tuesday, including Matthew Gall as CFO and Yvonne McGrath as VP of R&D. Gall was SVP of corporate development at Sarepta Therapeutics Inc. (NASDAQ:SRPT); McGrath was CSO of Complix...
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

With its parent company focused on small molecules for cancer, Taiho Ventures is using a recently upsized fund to find cutting edge modalities that take Taiho Pharmaceutical beyond its internal expertise. President Sakae Asanuma established...
BioCentury | May 27, 2020
Top Story

Arcus keeps its independence in deal that gives Gilead access to targets ripe for combinations

Gilead’s partnership with Arcus gives it access to a pipeline ripe for immuno-oncology combinations around closely watched targets, such as TIGIT. But the agreement doesn’t mirror Gilead’s last deal, in which partnering negotiations with Forty...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | Apr 16, 2020
Deals

Arcus mum on report of Gilead’s approach

Shares of oncology company Arcus rose sharply Thursday as the company remained quiet about a published report that said Gilead had approached it about a partnership or equity investment. Arcus Biosciences Inc. (NYSE:RCUS) gained $14.01...
BioCentury | Apr 14, 2020
Product Development

COVID-19 roundup: Can-Fite repurposing RA therapy; plus Brazilian chloroquine study points to cardiotoxicity, Athersys stem cell trial, Rutgers saliva test

...As Can-Fite begins testing the first ADORA3 agonist against COVID-19, the latest red flag for chloroquine...
...to receive either piclidenoson plus standard supportive care or supportive care alone. Can-Fite said the ADORA3...
...Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Targets ADORA3 - Adenosine A3 receptor Elizabeth...
Items per page:
1 - 10 of 315